Amarin (AMRN)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (-0.11%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.78 0.00 (-0.56%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 121 - 140 ( 361 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Do Not Miss Our Call Today at 2PM with the Go-To Patent Attorney
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Gearing Up to Push Back in Court Against Ruling for ANDA Filers
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Do Not Miss Our Apr. 15 Call at 2PM with the Go-To Patent Attorney
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare - Dial-in to Our Two Expert Calls Tomorrow: COVID-19 - Omega-3 at 12pm and 2pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Dial-in to Part 1 of our Omega-3 Expert Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and 20 Doc Calls Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
A Look at Judge Du''s Appeal Record While We Await Clarity on Next Steps
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Even With Court Win, Generics Still Have Rocky Road Ahead
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Dial In to Our Two Expert Calls This Week to Learn About FSGS and Omega-3s
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 8 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y